References
- DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37(6): 667–87
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53
- Clinical practice recommendations 2003. Diabetes Care 2003; 26(Supp 1): S1–156
- Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet- cell cytoplasm and glutamic acid decarboxylase for predication of insulin requirements in type 2 diabetes. Lancet 1997; 350(9087): 1288–93
- Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22(Supp1 2): B59–64
- Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99(20): 2626–32
- Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345(19): 1359–77
- Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose- response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997; 20(4): 597–606
References
- Riddle MC, Rosenstock J. Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Diabetes 2002; 51(Supp1 2): A113
- Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998; 21(7): 1052–7
- Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16(1): 21–31
- Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327(20): 1426–33
- Bastyr EJ 3rd, Johnson ME, Trautmann ME, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999; 21 (10): 1703–14
- Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin Ther 1999; 21(3): 523–34
- Hcrmansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25(5): 883–8